Hasegawa, Kiyoshi;
Takemura, Nobuyuki;
Yamashita, Tatsuya;
Watadani, Takeyuki;
Kaibori, Masaki;
Kubo, Shoji;
Shimada, Mitsuo;
Nagano, Hiroaki;
Hatano, Etsuro;
Aikata, Hiroshi;
Iijima, Hiroko;
Ueshima, Kazuomi;
Ohkawa, Kazuyoshi;
Genda, Takuya;
Tsuchiya, Kaoru;
Torimura, Takuji;
Ikeda, Masafumi;
Furuse, Junji;
Akahane, Masaaki;
Kobayashi, Satoshi;
Sakurai, Hideyuki;
Takeda, Atsuya;
Murakami, Takamichi;
Motosugi, Utaroh;
Matsuyama, Yutaka;
Kudo, Masatoshi;
Tateishi, Ryosuke.
The fifth version of the Clinical Practice Guidelines for Hepatocellular Carcinoma was revised by the Japan Society of Hepatology, according to the methodology of evidence-based medicine and partly to the Grading of Recommendations Assessment, Development and Evaluation system, which was published in Oct...
Zeng, Mei;
Xia, Jun;
Zong, Zhiyong;
Shi, Yi;
Ni, Yuxing;
Hu, Fupin;
Chen, Yijian;
Zhuo, Chao;
Hu, Bijie;
Lv, Xiaoju;
Li, Jiabin;
Liu, Zhengyin;
Zhang, Jing;
Yang, Wenjie;
Yang, Fan;
Yang, Qiwen;
Zhou, Hua;
Li, Xin;
Wang, Jianhua;
Li, Yimin;
Wang, Minggui.
The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group cov...
Zeng, Mei;
Xia, Jun;
Shi, YI;
Ni, Yuxing;
Fupin, Hu;
Chen, Yijian;
Li, Jiabin;
Zhang, Jing;
Yang, Fan;
Li, Xin;
Li, Yimin;
Wu, Anhua;
Wu, Depei;
Qiu, Haibo;
Wang, Minggui.
The dissemination of carbapenem-resistant Gram-negative bacilli (CRGNB) is a global public health issue. CRGNB isolates are usually extensively drug-resistant or pandrug-resistant, resulting in limited antimicrobial treatment options and high mortality. A multidisciplinary guideline development group cov...
NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. This is because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission....
Evidence-based recommendations on vutrisiran (Amvuttra) for treating hereditary transthyretin-related amyloidosis in adults.
Commercial arrangement
There is a simple discount patient access scheme for vutrisiran. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NH...
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.
Commercial arrangement
There is a simple discount patient access scheme for regorafenib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS or...
This guideline covers monitoring, treatment and follow-up for people aged 18 and over with Barrett’s oesophagus and stage 1 oesophageal adenocarcinoma. It includes advice on endoscopic and non-endoscopic techniques. It aims to improve outcomes by ensuring the most effective investigations and treatment...
Early value assessment (EVA) guidance on guided self-help digital cognitive behavioural therapy for children and young people with mild to moderate symptoms of anxiety or low mood.
NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance ...
Evidence-based recommendations on nivolumab (Opdivo) with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Commercial arrangement
There is a commercial arrangement for nivolumab. NHS organisations can get...
